NGR-hTNF (antitumor recombinant protein)

NGR-hTNF is an experimental antitumor drug designed to act on tumor blood vessels. It is a recombinant protein made by fusing the peptide CNGRCG to human tumor necrosis factor alpha. According to the source, it was in phase III clinical trials for relapsed malignant pleural mesothelioma, the cancer caused by exposure to asbestos, in 35 clinical centers across Europe, the United States, Canada and Egypt, and it was also being studied alone or with chemotherapy in four randomized phase II trials in other solid tumors. It has been granted orphan drug designation in both Europe and the United States. It is an investigational product, and nothing here is medical advice.